AUPH vs PVLA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AUPH · Aurinia Pharmaceuticals$14.70 ▼ 1.28%
PVLA · Palvella Therapeutics$142.85 ▼ 2.00%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AUPH -8.8%
- PVLA +45.7%
Head to head
| Metric | AUPH | PVLA |
|---|---|---|
| Price | $14.70 | $142.85 |
| Change today | ▼ 1.28% | ▼ 2.00% |
| Market cap | $1.97B | $2.09B |
| Return, 3 months | -11.3% | -2.0% |
| Return, year to date | -7.8% | +36.5% |
| Return, 1 year | -6.3% | +51.8% |
| P/E (TTM) | 6.4 | – |
| P/B | 3.0 | 10.6 |
| P/E percentile vs own 5y | 67th | 27th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +13.9% | – |
| Net profit growth (YoY) | +0.5% | -117.2% |
| Gross margin | 90.6% | – |
| Operating margin | 48.6% | – |
| Net margin | 97.7% | – |
| Return on equity | 61.4% | -63.4% |
| Analyst target vs. price | +29.3% | +59.4% |
| Analyst buy share | 67% | 100% |
| RSI (14) | 30 | 46 |
| 30-day volatility | 31.7% | 70.1% |
| Max drawdown, 1 year | -21.8% | -31.1% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PVLA is the largest of the group by market value.
- PVLA has returned the most over the past year.
- AUPH has been the calmest stock over the last 30 days.